Spatial mapping and geographic variation of inflammatory bowel disease in Canada: A population-based study

• Abstract

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients

• Abstracts
• Supplementary data

Graphical abstract

ECCO topical review on predictive models on IBD disease course and treatment response

• Abstract
• Supplementary data

Early Intestinal Ultrasound Response to Biologic and Small Molecule Therapy is Accurate to Predict Treat-To-Target Endoscopic Outcomes in Children with Ulcerative Colitis: Results from the Prospective Super Sonic-UC Study

• Abstract

Graphical Abstract

Expert Recommendations to Standardise Transcriptomic Analysis in Inflammatory Bowel Disease Clinical Trials

• Abstracts
• Supplementary data

Endoscopic submucosal dissection for visible dysplasia in IBD: A nationwide multicenter cohort from the GETAID and the SFED

• Abstract
• Supplementary data

Development and psychometric validation of a patient­reported outcome measure scale for Crohn's disease anorectal stricture

• Abstract
• Supplementary data

A Multicenter Study of the Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease

• Abstract
• Supplementary data

5-Aminosalicylates for non-Surgical Patients With Active or Quiescent Crohn’s Disease: An Overview Of Systematic Reviews (Umbrella Review)

• Abstracts
• Supplementary data

Graphic abstract

Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype

• Abstracts
• Supplementary data

Hidradenitis suppurativa among patients with new-onset inflammatory bowel disease - Results from the IBD Prognosis Study

• Abstracts
• Supplementary data

Graphical abstract

Graphical Abstract

Triple Biologic Therapy for Refractory Crohn’s Disease

• Abstract

Biglycan deficiency alleviates intestinal fibrosis through BMP-7-mediated Smad1/5/8 signaling

• Abstract
• Supplementary data

Histology in IBD: A Redundant Tool or a Valuable Prognostic Marker?

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn’s Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

• Abstracts
• Supplementary data